James M. Boyle - 16 Dec 2025 Form 4 Insider Report for Medline Inc. (MDLN)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MDLN
Reported as of: 16 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Mar 2026, 16:30:23 UTC
Next SEC filing: 17 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Nicole Fritz, Attorney-in-Fact

Key filing fact

James M. Boyle filed Form 4 for Medline Inc. (MDLN) on 06 Mar 2026.

Key facts

This page summarizes James M. Boyle's Form 4 filing for Medline Inc. (MDLN).
11 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 06 Mar 2026, 16:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002061052 Primary reporting owner

Boyle James M

Relationship: Chief Executive Officer, Director
Address: C/O MEDLINE INC., 3 LAKES DRIVE, NORTHFIELD
Signature: /s/ Nicole Fritz, Attorney-in-Fact
Signature date: 06 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDLN transaction

Class B Common Stock

Award

Transaction value
Shares: +24,313
Change %
Price
Shares after: 24,313
Date: 16 Dec 2025
Ownership: Direct
Footnotes: F1, F2

MDLN transaction

Class B Common Stock

Award

Transaction value
Shares: +514,876
Change %
Price
Shares after: 514,876
Date: 16 Dec 2025
Ownership: See Footnote
Footnotes: F1, F2, F3

MDLN transaction

Class A Common Stock

Award

Transaction value
Shares: +31,739
Change %
Price: $0.000000^*
Shares after: 31,739
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDLN transaction Derivative

Common Units of Medline Holdings, LP

Award

Transaction value
Shares: +24,313
Change %
Price
Shares after: 24,313
Date: 16 Dec 2025
Ownership: See Footnote
Underlying class: Class A Common Stock
Underlying amount: 24,313
Exercise price
Footnotes: F1, F5

MDLN transaction Derivative

Common Units of Medline Holdings, LP

Award

Transaction value
Shares: +514,876
Change %
Price
Shares after: 514,876
Date: 16 Dec 2025
Ownership: See Footnote
Underlying class: Class A Common Stock
Underlying amount: 514,876
Exercise price
Footnotes: F1, F3, F5

MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares: +1,201,584
Change %
Price
Shares after: 1,201,584
Date: 16 Dec 2025
Ownership: See Footnote
Underlying class: Class A Common Stock
Underlying amount: 1,201,584
Exercise price: $15.42
Footnotes: F1, F6, F7, F8

MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares: +340,407
Change %
Price
Shares after: 340,407
Date: 16 Dec 2025
Ownership: See Footnote
Underlying class: Class A Common Stock
Underlying amount: 340,407
Exercise price: $15.23
Footnotes: F1, F6, F7, F9

MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares: +1,146,379
Change %
Price
Shares after: 1,146,379
Date: 16 Dec 2025
Ownership: See Footnote
Underlying class: Class A Common Stock
Underlying amount: 1,146,379
Exercise price: $16.49
Footnotes: F1, F6, F7, F10

MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares: +252,481
Change %
Price
Shares after: 252,481
Date: 16 Dec 2025
Ownership: See Footnote
Underlying class: Class A Common Stock
Underlying amount: 252,481
Exercise price: $19.01
Footnotes: F1, F6, F7, F11

MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares: +183,699
Change %
Price
Shares after: 183,699
Date: 16 Dec 2025
Ownership: See Footnote
Underlying class: Class A Common Stock
Underlying amount: 183,699
Exercise price: $27.68
Footnotes: F1, F6, F7, F12

MDLN transaction Derivative

Incentive Units of Medline Holdings, LP

Award

Transaction value
Shares: +1,057,309
Change %
Price
Shares after: 1,057,309
Date: 16 Dec 2025
Ownership: See Footnote
Underlying class: Class A Common Stock
Underlying amount: 1,057,309
Exercise price: $15.42
Footnotes: F1, F3, F6, F7, F13

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 13 footnotes

Footnote F1

These securities were acquired in connection with the reclassification of the interests of Medline Holdings, LP prior to the Issuer's initial public offering (as more fully described in the Registration Statement on Form S-1). These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025.

Footnote F2

Shares of the Issuer's Class B common stock ("Class B Common Stock") have no economic value and have one vote per share. One share of Class B Common Stock is issued for each common unit of Medline Holdings, LP ("Common Units") held. Upon an exchange of Common Units for shares of the Issuer's Class A common stock ("Class A Common Stock"), an equivalent number of shares of Class B Common Stock held by such holder will be automatically cancelled.

Footnote F3

These securities are held by a family trust of which the Reporting Person's spouse is the trustee.

Footnote F4

Represents a grant of restricted stock units ("RSUs"), of which 25% vest on June 15, 2026 and the remaining 75% vest in three equal annual installments beginning on March 1, 2027.

Footnote F5

Pursuant to the terms of an exchange agreement, dated as of December 16, 2025 (the "Exchange Agreement"), holders have the right to exchange their Common Units for shares of the Class A Common Stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire. Such Common Units are held indirectly through Medline Management Aggregator LLC.

Footnote F6

Reflect incentive units of Medline Holdings, LP ("Incentive Units"), which are "profit interests" having economic characteristics similar to stock appreciation rights. Vested Incentive Units are convertible, at the holder's election, into a number of Common Units generally equal to (a) the product of the number of vested Incentive Units to be converted with a given per unit participation threshold and then-current difference between the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock) and the per unit participation threshold of such vested Incentive Units divided by (b) the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock), subject to certain adjustments.

Footnote F7

(Continued from Footnote 6 above) Common Units are exchangeable on a one-for-one basis for shares of Class A Common Stock pursuant to the terms of the Exchange Agreement. These Incentive Units have no expiration date. Such Incentive Units are held indirectly through Medline Management Aggregator LLC.

Footnote F8

62% of these Incentive Units have vested, and the remaining 38% vest on October 21, 2026.

Footnote F9

40% of these Incentive Units have vested, and the remaining 60% vest in three equal annual installments beginning on April 1, 2026.

Footnote F10

40% of these Incentive Units have vested, and the remaining 60% vest in three equal annual installments beginning on October 1, 2026.

Footnote F11

20% of these Incentive Units have vested, and the remaining 80% vest in four equal annual installments beginning on March 29, 2026.

Footnote F12

These Incentive Units vest in five equal annual installments beginning on March 28, 2026.

Footnote F13

These Incentive Units are fully vested.